Tratamiento del asma severo con Omalizumab: experiencia pediátrica en Chile y revisión de la literatura

Revista Chilena de Enfermedades Respiratorias

CRUZ B, CAROLINA¹  CAMPUSANO T, LUIS¹  HERRERA G, ANA MARÍA²  PERILLÁN T, JOSÉ ANTONIO³  LEZANA S, VIVIANA⁴  ÁLVAREZ G, CECILIA⁴  MARINOVIC M, MARÍA ANGÉLICA⁵  NAVARRETE C, PAMELA⁶  HERNÁNDEZ C, JURY⁷ 

[1] Clínica Alemana de Santiago, Santiago, Chile;Clínica Santa María, Chile;Complejo Asistencial Dr. Víctor Ríos Ruiz, Los Ángeles, Chile;Hospital San Juan de Dios, Chile;Universidad de Chile, Santiago, Chile;Universidad de Valparaíso, Valparaíso, Chile;Universidad de los Andes, Chile

关键词: Omalizumab;    asthma;    anti-asthmatic agents;    antibodies;    anti-idiotypic;    child;    quality of life.;   

DOI  :  10.4067/S0717-73482016000300004

学科分类：社会科学、人文和艺术（综合）

来源: Sociedad Chilena de Enfermedades Respiratorias

【 摘 要 】

This paper presents clinical experience with Omalizumab treatment in 8 pediatric patients in Chile. All children presented difficult to control asthma despite receiving high intensity treatment, with low quality of life. All patients were studied in order to discard errors in asthma diagnosis and to evaluate asthma treatment adherence and inhalation technique. After evaluation, patients proven to have severe therapy resistant asthma were indicated treatment with Omalizumab. Significant clinical improvement was observed, with reduced asthma symptoms and number of exacerbations, as well as an improved quality of life. Omalizumab showed a good safety profile with mild and transient adverse reactions in 6 administrations of a total of 122.

【 授权许可】

CC BY